Receptor Life Sciences
Facts
- HQ
- Seattle, WA, US
- Sectors
- Biotechnology, Pharmaceuticals
- Stage
- Series A
- Members see funding amounts. .
Is this your organization? Claim it
Receptor Life Sciences raises $29M Series A to advance inhaled dry‑powder cannabinoid medicines and start FDA IND process
Receptor Life Sciences, led by CEO Gregory Wesner, raised $29 million in its first Series A to advance an inhaler delivering dry powdered cannabinoid medicines and begin the FDA investigational new drug process while formalizing collaborations in Canada and Europe.
Stealth biotech Receptor Life Sciences raises $7.5M to develop inhalable plant-extract pharmaceuticals targeting pain, CNS and chemo side effects
Receptor Life Sciences, a stealthy Seattle-area biotech founded in 2015, raised just over $7.5 million and is developing inhalable pharmaceutical preparations derived from plant extracts to treat conditions including pain, CNS and metabolic and gastrointestinal disorders, and chemotherapy side effects. The company declined to name investors or disclose the specific plant, lists minimal public personnel, and had a USPTO appeal to trademark its name rejected.